Literature DB >> 7528712

Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue.

W J Sandborn1, G M Lawson, T J Cody, M K Porayko, J E Hay, G J Gores, J L Steers, R A Krom, R H Wiesner.   

Abstract

We have previously reported that low hepatic tissue cyclosporine levels correlate with early cellular rejection after liver transplantation. The aim of this study is to determine whether there is a similar relationship in patients treated with FK506. Twenty-five liver biopsies were performed in 10 patients immunosuppressed with FK506 without cellular rejection: day 7 = 10; day 14 = 3; day 21 = 9; day 28 = 1; day 35 = 1; and day 42 = 1. These 10 patients without cellular rejection were compared with 7 patients immunosuppressed with FK506 with cellular rejection who underwent a total of 23 liver biopsies, including 9 biopsies that showed rejection: day 7 = 4; day 14 = 2; day 21 = 1; day 28 = 1; and day 49 = 1. There was no significant difference between the nonrejection and current rejection groups in the median plasma concentration of FK506, 0.9 ng/mL versus 0.9 ng/mL (P = .50). In contrast, the median hepatic tissue concentration of FK506 was significantly higher in the nonrejection group than it was in the current rejection group, 144 ng/g versus 48 ng/g (P = .02). In the current rejection group, 7 of 9 hepatic tissue concentrations of FK506 were < 100 ng/g, and in the nonrejection group, 18 of 25 hepatic tissue concentrations were > 100 ng/g. Low hepatic tissue concentrations of FK506 correlate with the occurrence of early cellular rejection after liver transplantation, in contrast to plasma concentrations of FK506. A hepatic tissue concentration of FK506 < 100 ng/g is 78% sensitive and 72% specific for cellular rejection.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7528712

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

Review 1.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 2.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance.

Authors:  Marie Antignac; Jean Sebastien Hulot; Emmanuel Boleslawski; Laurent Hannoun; Yvan Touitou; Robert Farinotti; Philippe Lechat; Saïk Urien
Journal:  Eur J Clin Pharmacol       Date:  2005-07-01       Impact factor: 2.953

Review 4.  Interpreting tacrolimus concentrations during pregnancy and postpartum.

Authors:  Mary F Hebert; Songmao Zheng; Karen Hays; Danny D Shen; Connie L Davis; Jason G Umans; Menachem Miodovnik; Kenneth E Thummel; Thomas R Easterling
Journal:  Transplantation       Date:  2013-04-15       Impact factor: 4.939

5.  Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the 1st month following renal transplantation.

Authors:  Benedetta C Sallustio; Benjamin D Noll; Janet K Coller; Jonathan Tuke; Graeme Russ; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2019-03-06       Impact factor: 4.335

Review 6.  Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS.

Authors:  Mwlod Ghareeb; Fatemeh Akhlaghi
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

Review 7.  Renal dysfunction associated with liver transplantation.

Authors:  R M Jindal; I Popescu
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401

Review 8.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Tacrolimus-related adverse effects in liver transplant recipients: its association with trough concentrations.

Authors:  Joy Varghese; Mettu Srinivasa Reddy; Kota Venugopal; Rajasekhar Perumalla; Gomathy Narasimhan; Olithselvan Arikichenin; Vivekanandan Shanmugam; Naresh Shanmugam; Vijaya Srinivasan; Venkataraman Jayanthi; Mohamed Rela
Journal:  Indian J Gastroenterol       Date:  2014-04-18

Review 10.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.